Efficacy and Safety of Zoledronic Acid in the Prevention and Treatment of Corticosteroid Induced Osteoporosis

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2004
The intake of high doses of corticosteroids is known to play an important role in the weakening of the bones and is thus an increasing fracture risk. Zoledronic acid (Aclasta) is a drug known for its protective effect in some bone diseases (tumors, paget). This study will test the safety and efficacy of zoledronic acid in the prevention and treatment of corticosteroid induced osteoporosis in male and female patients.
Epistemonikos ID: 0fee1213d76179ed28052c4187ad5b3cd7a0967b
First added on: May 04, 2024